Historically, diagnosis has primarily relied on cognitive changes, which manifest at a later stage of the disease. Biomarker-based diagnostics were initially limited to specialized clinics capable of performing cerebrospinal fluid sampling or PET scans. However, their ability to determine the disease stage and predict disease progression remains limited, especially when compared to PET scans. The researchers used two independent international cohorts with data from a novel immunoassay platform that measures more than 120 inflammation and neuronal markers in a single blood sample. The study results show that including additional proteins significantly improved the ability of p-tau217 to predict advanced tau pathology in individuals with elevated levels of amyloid plaques.